Publications by authors named "Kristin Hueftle"
Background: The aims of this study were to assess the safety and tolerability of nanoparticle albumin bound paclitaxel (nab-paclitaxel), doxorubicin, and cyclophosphamide as combination therapy for breast cancer patients in the neoadjuvant setting and to assess the overall clinical response and pathologic complete response (pCR).
Patients And Methods: Twenty-six women with newly diagnosed stage II to III histologically or cytologically proven adenocarcinoma of the breast with negative HER2 status were enrolled. Patients were treated with nab-paclitaxel 100 mg/m, doxorubicin 50 mg/m, and cyclophosphamide 500 mg/m on day 1 and nab-paclitaxel 100 mg/m on day 8 in a 21-day cycle for 6 cycles total.